Cargando…

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options

BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincenzi, Bruno, Frezza, Anna Maria, Schiavon, Gaia, Santini, Daniele, Dileo, Palma, Silletta, Marianna, Delisi, Delia, Bertoldo, Francesco, Badalamenti, Giuseppe, Baldi, Giacomo Giulio, Zovato, Stefania, Berardi, Rossana, Tucci, Marco, Silvestris, Franco, Dei Tos, Angelo Paolo, Tirabosco, Roberto, Whelan, Jeremy Simon, Tonini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637638/
https://www.ncbi.nlm.nih.gov/pubmed/23594799
http://dx.doi.org/10.1186/2045-3329-3-6
_version_ 1782475773997744128
author Vincenzi, Bruno
Frezza, Anna Maria
Schiavon, Gaia
Santini, Daniele
Dileo, Palma
Silletta, Marianna
Delisi, Delia
Bertoldo, Francesco
Badalamenti, Giuseppe
Baldi, Giacomo Giulio
Zovato, Stefania
Berardi, Rossana
Tucci, Marco
Silvestris, Franco
Dei Tos, Angelo Paolo
Tirabosco, Roberto
Whelan, Jeremy Simon
Tonini, Giuseppe
author_facet Vincenzi, Bruno
Frezza, Anna Maria
Schiavon, Gaia
Santini, Daniele
Dileo, Palma
Silletta, Marianna
Delisi, Delia
Bertoldo, Francesco
Badalamenti, Giuseppe
Baldi, Giacomo Giulio
Zovato, Stefania
Berardi, Rossana
Tucci, Marco
Silvestris, Franco
Dei Tos, Angelo Paolo
Tirabosco, Roberto
Whelan, Jeremy Simon
Tonini, Giuseppe
author_sort Vincenzi, Bruno
collection PubMed
description BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. RESULTS: The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (range 1–9). The most common SRE was the need for radiotherapy (28%) followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1–14). SREs were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105). CONCLUSIONS: This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates in this setting.
format Online
Article
Text
id pubmed-3637638
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36376382013-04-28 Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options Vincenzi, Bruno Frezza, Anna Maria Schiavon, Gaia Santini, Daniele Dileo, Palma Silletta, Marianna Delisi, Delia Bertoldo, Francesco Badalamenti, Giuseppe Baldi, Giacomo Giulio Zovato, Stefania Berardi, Rossana Tucci, Marco Silvestris, Franco Dei Tos, Angelo Paolo Tirabosco, Roberto Whelan, Jeremy Simon Tonini, Giuseppe Clin Sarcoma Res Research BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. RESULTS: The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (range 1–9). The most common SRE was the need for radiotherapy (28%) followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1–14). SREs were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105). CONCLUSIONS: This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates in this setting. BioMed Central 2013-04-17 /pmc/articles/PMC3637638/ /pubmed/23594799 http://dx.doi.org/10.1186/2045-3329-3-6 Text en Copyright © 2013 Vincenzi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Vincenzi, Bruno
Frezza, Anna Maria
Schiavon, Gaia
Santini, Daniele
Dileo, Palma
Silletta, Marianna
Delisi, Delia
Bertoldo, Francesco
Badalamenti, Giuseppe
Baldi, Giacomo Giulio
Zovato, Stefania
Berardi, Rossana
Tucci, Marco
Silvestris, Franco
Dei Tos, Angelo Paolo
Tirabosco, Roberto
Whelan, Jeremy Simon
Tonini, Giuseppe
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
title Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
title_full Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
title_fullStr Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
title_full_unstemmed Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
title_short Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
title_sort bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637638/
https://www.ncbi.nlm.nih.gov/pubmed/23594799
http://dx.doi.org/10.1186/2045-3329-3-6
work_keys_str_mv AT vincenzibruno bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT frezzaannamaria bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT schiavongaia bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT santinidaniele bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT dileopalma bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT sillettamarianna bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT delisidelia bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT bertoldofrancesco bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT badalamentigiuseppe bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT baldigiacomogiulio bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT zovatostefania bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT berardirossana bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT tuccimarco bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT silvestrisfranco bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT deitosangelopaolo bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT tiraboscoroberto bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT whelanjeremysimon bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions
AT toninigiuseppe bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions